Claims against Dr Reddy’s over Revlimid in US dismissed
On 22nd December, 2022 and 27th December, 2022, the plaintiffs voluntarily dismissed Dr Reddy’s Laboratories Limited and Dr…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Dr Reddy’s Laboratories
Anti-trust litigation filed against Dr Reddy’s Laboratories and other generic pharma companies in US
The complaint seeks damages for purported overpayments and equitable relief
Indian drug 2DG can reduce heart damage by coronavirus, find US researchers
Their findings, based on research with fruit flies and mouse heart cells, were published in 'Communications Biology,' a 'Nature'…
Dr Reddy’s lines up Rs 1,500 crore capex to focus on biosimilars and injectables
The drug major also plans to utilise the capital for adding capacities to existing plants, firm up R&D activities and further…
Dr Reddy’s announces financial results for Q2 and H1 FY23
EBITDA is at Rs 19.3 billion and the EBITDA margin is 30.6 per cent
Three pharma companies recall products in US
The three pharma companies -- Dr Reddy's Laboratories, Cipla and Aurobindo Pharma -- are recalling different products in the US…
IQVIA and Dr Reddy’s partner for CRM solution
Dr Reddy’s will rollout IQVIA’s OCE application to its entire field force and marketing users in India to drive more meaningful…
Dr Reddy’s Laboratories enters into licensing agreement with Slayback Pharma
The partnership aims to obtain exclusive rights in the first-to-file ANDA for the private label version of Lumify in the US
Dr Reddy’s announce launch of Bortezomib for injection, 3.5 mg single-dose vial in US
Bortezomib for injection is a proteasome inhibitor indicated for the treatment of adult patients with multiple myeloma and mantle…
Business sustainability through compliance, process excellence and process simplification
As India Parma Inc strives to transform into a more value-led and innovation-driven industry, it has to develop strategic…